SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility following a press address where the administration indicated a prolonged military commitment in the Middle East, sparking investor concerns over potential energy inflation and long-term geopolitical instability. Market participants are actively debating whether this signals a genuine shift in economic conditions or if it is another instance of price manipulation, with many choosing to avoid holding positions over the upcoming long holiday weekend.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is facing intense volatility as market participants react to ongoing uncertainty surrounding the administration's military rhetoric in the Middle East and shifting geopolitical alliances. Community discourse is heavily polarized, with active debates ranging from concerns over interest rate policies and inflationary pressures to fierce criticism of presidential communications and the broader impact of current geopolitical tensions on the markets.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is trading amid intense speculation surrounding a high-stakes televised address from President Trump, with the community deeply divided over whether the speech will signal a genuine de-escalation of the Iran conflict or a continuation of hostilities. While bullish participants are banking on a potential peace-driven rally, many traders are positioning defensively, citing concerns over market manipulation, elevated oil prices, and the possibility of a volatile "sell the news" event over the upcoming holiday weekend.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense social media debate as investors react to geopolitical instability and shifting political rhetoric surrounding current conflict zones. Community members are actively split between long-term holders advocating for dollar-cost averaging and traders attempting to navigate the price swings driven by potential military announcements and market-wide uncertainty.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors weigh an upcoming delivery report against broader geopolitical tensions and market volatility following recent executive announcements. Community discussion is sharply divided between those banking on a delivery beat to drive a rebound and skeptics who are wary of valuation concerns and the company's long-term competitive positioning.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing investor attention as the semiconductor sector rebounds from recent geopolitical volatility, with the community actively debating the stock's resilience amid broader concerns about market manipulation and upcoming high-profile policy announcements. Market participants are split between bullish sentiment fueled by aggressive AI infrastructure spending and bearish skepticism regarding the stock's ability to maintain gains in the face of ongoing macroeconomic uncertainty.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as investors react to a significant strategic move to repurchase full control of its Fab 34 facility in Ireland for over $14 billion, a deal aimed at bolstering its manufacturing capacity and long-term foundry competitiveness. While the stock saw a positive reaction to the news, market participants are actively debating the move's impact on Intel's balance sheet, its potential to secure future high-value customers, and broader volatility driven by geopolitical tensions in the Middle East.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate, driven by skepticism over its aggressive dilution strategy alongside a broader market correction impacting crypto-linked equities. Investors are currently polarized, with some aggressively buying the dip in anticipation of a potential bounce, while vocal bears argue that the firm's reliance on debt and share issuance to fund BTC purchases creates long-term structural risk.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing a volatile recovery as investors pivot between speculative war-related macro concerns and bullish enthusiasm regarding sold-out memory capacity and AI-driven supply demand. The community is sharply divided, with bulls pointing to strong fundamental demand and institutional call-buying, while bears remain skeptical of recent price action and persistent geopolitical instability.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense bearish pressure following a weak earnings outlook and concerns over declining demand in key markets like China, fueling significant community debate over whether the stock is a value trap or a long-term bargain. Investors are actively discussing the company's dividend stability, management performance, and the potential impact of ongoing tariff tensions, with many tracking key support levels while attempting to time a rebound.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI and Biotech Enter a Stock Picker’s Market

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...

Why Is Lantern Pharma Stock Soaring Monday?

Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.read more...

<ul class="summary-bullets"><li>PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation.</li><li>Iterum Therapeutics announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.</li><li>Lantern Pharma said the FDA cleared its Investigational New Drug application for STAR-001, a targeted therapy for relapsed or refractory CNS cancers.</li></ul>U.S. equities were in the green in Monday’s pre-market trade amid the ongoing tensions in the Middle East, with President Donald Trump stating on Sunday that Iran had agreed to the 15-point ceasefire plan “for the most part.”At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.49%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.42%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.47%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ELAB">PMGC Holdings Inc. (ELAB)</a>PMGC Holdings shares soared more than 66% in Monday’s pre-market session. The company announced on Friday that its wholly-owned subsidiary, NorthStrive Biosciences, has amended its existing agreement with MOA Life Plus for human clinical trials of its lead candidate EL-22, as well as EL-32, to study the preservation of muscle and lean mass.<a href="https://stocktwits.com/symbol/ELAB">ELAB stock</a> is down 95% year-to-date.<a href="https://stocktwits.com/symbol/ITRM">Iterum Therapeutics PLC (ITRM)</a>Iterum Therapeutics shares more than doubled to soar 110% in Monday’s pre-market trade. The company announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.<a href="https://stocktwits.com/symbol/ITRM">ITRM stock</a> is down 90% year-to-date.<a href="https://stocktwits.com/symbol/LTRN">Lantern Pharma Inc. (LTRN)</a>Lantern Pharma shares gained more than 17% in Monday’s pre-market session. The company announced on Friday that its CEO Panna Sharma continues to serve the Dallas-based biopharmaceutical company. It also announced that the U.S. Food and Drug administration (FDA) cleared its Investigational New Drug (IND) application for STAR-001, its treatment for patients with relapsed or refractory central nervous system (CNS) malignancies.<a href="https://stocktwits.com/symbol/LTRN">LTRN stock</a> is down 63% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bur-stock-sinks-after-us-appeals-court-ruling-argentina-ypf-connection/cZ3HJ4aRIm7">BUR Stock Sinks 40% Following A Reported US Appeals Court Ruling — What Is The Argentina Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Soaring Before The Bell

U.S. equities gained in Monday’s pre-market trade after President Donald Trump stated that Iran had agreed to the 15-point proposal for the most part.

Equity

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AIdriven, clinicalstage oncology company leveraging its proprietary RADR platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on...

Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001

(RTTNews) - Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

<ul class="summary-bullets"><li>STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform.</li><li>The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone.</li><li>The trial to be conducted with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.</li></ul>Shares of Lantern Pharma Inc. (LTRN) surged nearly 18% in pre-market trading on Friday after the biotech firm said that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers.STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform, which helped identify its potential in CNS and pediatric CNS indications, the company said. The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone in children with relapsed or refractory CNS cancers.The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.<h2 class="st-heading-2">Lantern's Drug To Treat Soft Tissue Sarcomas</h2>Earlier this year, the FDA granted Orphan Drug Designation to Lantern Pharma's experimental drug LP-284 for the treatment of soft tissue sarcomas. It marked the third orphan designation for LP-284 and the sixth across the company’s pipeline.Orphan designation provides incentives to support the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S.LP-284 is a small-molecule therapy designed to target cancer cells with DNA repair defects. The drug has shown encouraging activity in early studies, including a complete response in a heavily pretreated lymphoma patient in a Phase 1 trial.The therapy is currently being tested in patients with B-cell non-Hodgkin lymphomas.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/LTRN">LTRN</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/LTRN_jpg_fb27c74f09.webp" alt="LTRN.jpg">The stock has been under heavy selling pressure, slumping more than 50% in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

LTRN Stock Gains 18% Pre-Market: FDA Greenlights First Pediatric Cancer Trial For Oncology Compound

The U.S. Food and Drug Administration cleared its Investigational New Drug application for Lantern Pharma’s oncology compound, paving the way for a Phase 1 clinical trial.

Why Did LTRN Stock Surge 18% In Pre-Market Today? 

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the...

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...

$LTRN Q4 &#39;25 Earnings Results &amp; Recap

Lantern Pharma expects existing cash, cash equivalents, and marketable securities to fund operations until late July to mid-September 2026, requiring substantial additional funding in the near future.

Stocktwits

Lantern Pharma Inc

 Q4 '25 Earnings Results & Recap

Lantern Pharma expects existing cash, cash equivalents, and marketable securities to fund operations until late July to mid-September 2026, requiring substantial additional funding in the near future.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

LTRN
Lantern Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest LTRN News

LTRNLantern Pharma Inc